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Identification of radiosensitization target genes and siRNAs. siRNA 
library screen for candidates in DU145 cells. Cells were transfected 
with library siRNAs or controls. Transfected cells were untreated or 
irradiated (6 Gy) 72 hours later. Radiosensitization was calculated as 
percent increased cell death associated with a gene-specific siRNA 
after radiation therapy compared with irradiated cells transfected with 
a control siRNA. Each diamond represents an siRNA (triplicate, aver-
age) organized alphabetically. Mean library radiosensitization and SD 
are shown by solid and dashed lines, respectively.
Figure 2
Clonogenic survival assays. (A–F) Radiosensitization was confirmed by clonogenic survival assays (n = 3). DU145 cells were reverse transfected 
with 5 nM control siRNA or (A) DNAPK, (B) MAD2L2, (C) BRCA2, (D) NBN, (E) RAD23B, or (F) RAD54L siRNA 72 hours prior to irradiation. 
DMF0.1 values are shown for each. Open diamonds, control siRNA; closed squares, candidate siRNA. SF, surviving fraction.
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Figure 3
Aptamer-shRNA chimeras and PSMA-targeted DNA repair gene knockdown. (A and B) Secondary structure of (A) A10-3–DNAPK and (B) 
Neg-DNAPK. Aptamer and shRNA portions are shown by brackets. (C–F) Aptamer-shRNA chimera–mediated RNAi in the absence of transfec-
tion reagents. (C) LNCaP cells were treated with 0, 4, 40, or 400 nM A10-3–DNAPK for 48 hours, and DNAPK mRNA levels were quantified by 
qRT-PCR. LNCaP cells were treated with 400 nM of (D) A10-3–DNAPK, (E) A10-3–BRCA2, or (F) A10-3–ATM for 48 hours. Respective target 
gene mRNA levels were quantified by qRT-PCR. Appropriate siRNAs were transfected (100 nM) as positive controls. Expression is normalized 
to GAPDH. Mean ± SEM (n = 3). *P < 0.05.
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PSMA selectivity and aptamer-shRNA chimera processing. (A and B) PSMA selectivity. (A) PC3-PIP or (B) PC3-Flu cells were treated with 
400 nM aptamer-shRNA chimeras for 48 hours, and DNAPK expression was quantified by qRT-PCR. siRNA DNAPK (100 nM transfected) was 
included as a positive control. Expression is normalized to GAPDH. Mean ± SEM (n = 3). *P < 0.05. (C) Aptamer-shRNA chimera processing 
by Dicer in vitro. Cleavage products were analyzed by denaturing PAGE and ethidium bromide staining. Image is inverted for clarity. (D) Cell-
based RNAi processing assay. LNCaP cells were treated with 400 nM aptamer-shRNA chimeras, and RNA was extracted 48 hours later for 
Northern blot assay. Probes are specific to corresponding antisense siRNAs. ds, double-stranded; ss, single-stranded. (E and F) Targeted in vivo 
knockdown. Subcutaneous LNCaP tumors were injected with aptamer-shRNA chimeras (200 pmol/injection) on days –3 and –2 and harvested 
on day 0, and DNAPK expression was determined. (E) qRT-PCR. Mean ± SEM. *P < 0.05. (F) Immunohistochemistry. Original magnification, 
×400. (G and H) 5′-RACE PCR analysis to assess siRNA-mediated cleavage of DNAPK. (G) LNCaP cells transfected with DNAPK siRNA or with 
A10-3–DNAPK chimeras produced a specific DNAPK cleavage product. (H) In vivo treatment of LNCaP xenografts with A10-3–DNAPK chimera 
resulted in siRNA-mediated DNAPK cleavage.
Downloaded on June 19, 2014.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/45109
research article








































Radiosensitization in PCa cell and tumor models. (A) In vitro radiosensitization. LNCaP cells treated with 400 nM A10-3–DNAPK or A10-3–Con 
or transfected with control siRNA were irradiated 48 hours later with 6 Gy IR, and cell viability was assessed 12 days later by MTS. Percent cell 
death is relative to nonirradiated cells. (B–D) In vivo radiosensitization. Established tumors were treated with aptamer-shRNA chimeras (days –3 
and –2) and either 6 Gy IR or no radiation (day 0). (B) PC3 tumor model (n = 3 per group). A10-3–DNAPK provided no significant therapeutic ben-
efit to nonirradiated or irradiated PC3 tumors. Radiation similarly affected growth in all treatment groups. Mean ± SEM. (C) LNCaP tumor model 
(n ≥ 6 per group). Radiation similarly affected growth in all treatment groups except irradiated A10-3–DNAPK. *P < 0.05, ***P < 0.001, A10-3– 
DNAPK IR vs. A10-3–Con IR and A10-3–DNAPK IR vs. Neg-DNAPK IR; 2-way ANOVA. Mean ± SEM. (D) Extension of tumor quadrupling for 
LNCaP tumor model. Events (animals whose tumor volume was not yet 4-fold the size at injection) were plotted by Kaplan-Meier curve. P < 0.01, 
A10-3–Con IR vs. A10-3–Con and Neg-DNAPK IR vs. Neg-DNAPK; P < 0.0001, A10-3–DNAPK IR vs. A10-3–Con IR and A10-3–DNAPK IR vs. 
Neg-DNAPK IR; log-rank (Mantel-Cox) test.
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Ex vivo treatment of human prostate tissue. Sections of normal human prostate tissue were obtained from fresh radical prostatectomy specimens 
and maintained ex vivo. These were treated with 200 nM aptamer-shRNA chimeras, and DNAPK levels were detected by immunohistochemistry 
48 hours after treatment. Quantitative image analysis determined a 25% reduction in DNAPK staining for A10-3–DNAPK–treated samples. 
Original magnification, ×400.
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